FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286295292> ?p ?o ?g. }

• W4286295292 endingPage "e18013" @default.
• W4286295292 startingPage "e18013" @default.
• W4286295292 abstract "e18013 Background: Cetuximab significantly improved survival outcomes of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) when combined with chemotherapy. The aim of this study was to explore clinical outcomes, prognostic factors, and risk stratification model for R/M HNSCC patients who received cetuximab-containing regimens based on a real-world, multicenter Taiwanese patient cohort. Methods: This is a retrospective study involving 12 oncology institutions in Taiwan. All R/M HNSCC patients who received cetuximab-containing regimens from January 2017 to December 2020 were included in this study. Prognostic factors were evaluated by univariate/ multivariate analysis. The factors that showed significant differences (p < 0.05) were selected to establish the prediction model. The receiver operating characteristic (ROC) curve was obtained to select cut-off values as a reference for continuous variables. The risk score system incorporated both continuous and categorical factors. The score was determined according to hazard ratio. Results: A total of 818 R/M HNSCC patients were included in this study. Patient characteristics were as following: median age, 56 years; performance status (PS) 0/1/≧2, 16.0%/70.4%/13.3%; oral/ oropharynx/ hypopharynx/ larynx/ others, 51.5%/17.5%/19.7%/6.4%/5.0%; stage at initial diagnosis (AJCC8), 0/I/II/III/IVA/IVB/IVC/unknown, 0.2%/5.9%/8.1%/7.1%/ 35.5%/18.0%/6.7%/18.6%; locoregional recurrence/ distant metastasis/ unknown, 38.4%/ 56.0%/ 5.6%; site of distant metastasis, lung/ distant lymph node/ bone/ liver/ skin/ brain, 60.3%/ 37.1%/ 18.8%/ 6.3%/ 8.1%/ 3.3%; cetuximab-PF/ cetuximab-non-PF regimen, 56.6%/ 43.4%. The median overall survival (mOS) was 10.0 months (95% confidence interval [CI] 9.1-10.9 months). Multivariate analysis disclosed poor prognostic factors on OS, including poor PS, smoking history, R2 resection of primary surgery, present distant metastasis at bone, cetuximab combined with non-PF regimen. In addition, HB and neutrophil to lymphocyte ratio (NLR) were shown to have significant difference between treatment responders and non-responders (inc. SD pts). Risk-stratification model was established including factors: PS, smoking history, bone metastasis, hemoglobin level, and NLR. The mOS of the three risk groups stratified from the prediction model were 13.0/7.0/4.0 months (p < 0.001). Conclusions: Poor prognostic factors for R/M HNSCC treated with cetuximab-based regimens includes poor PS, smoking history, R2 resection of primary surgery, bone metastasis, and non-PF regimen. In this study, the risk-stratification model for cetuximab-based treatment was established using some of the identified prognostic factors help to predict the overall survival for R/M HNSCC patients." @default.
• W4286295292 created "2022-07-21" @default.
• W4286295292 creator A5003861667 @default.
• W4286295292 creator A5012781741 @default.
• W4286295292 creator A5013493910 @default.
• W4286295292 creator A5016212774 @default.
• W4286295292 creator A5018015928 @default.
• W4286295292 creator A5028840611 @default.
• W4286295292 creator A5029215411 @default.
• W4286295292 creator A5029716433 @default.
• W4286295292 creator A5030139791 @default.
• W4286295292 creator A5030670961 @default.
• W4286295292 creator A5042398989 @default.
• W4286295292 creator A5042746005 @default.
• W4286295292 creator A5046880629 @default.
• W4286295292 creator A5059744187 @default.
• W4286295292 creator A5061542841 @default.
• W4286295292 creator A5068212661 @default.
• W4286295292 creator A5075505594 @default.
• W4286295292 creator A5076979086 @default.
• W4286295292 creator A5084216361 @default.
• W4286295292 creator A5089886091 @default.
• W4286295292 date "2022-06-01" @default.
• W4286295292 modified "2023-10-17" @default.
• W4286295292 title "A real-world study of prognostic factors and risk-stratification model from Taiwanese patients with recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regimen." @default.
• W4286295292 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e18013" @default.
• W4286295292 hasPublicationYear "2022" @default.
• W4286295292 type Work @default.
• W4286295292 citedByCount "0" @default.
• W4286295292 crossrefType "journal-article" @default.
• W4286295292 hasAuthorship W4286295292A5003861667 @default.
• W4286295292 hasAuthorship W4286295292A5012781741 @default.
• W4286295292 hasAuthorship W4286295292A5013493910 @default.
• W4286295292 hasAuthorship W4286295292A5016212774 @default.
• W4286295292 hasAuthorship W4286295292A5018015928 @default.
• W4286295292 hasAuthorship W4286295292A5028840611 @default.
• W4286295292 hasAuthorship W4286295292A5029215411 @default.
• W4286295292 hasAuthorship W4286295292A5029716433 @default.
• W4286295292 hasAuthorship W4286295292A5030139791 @default.
• W4286295292 hasAuthorship W4286295292A5030670961 @default.
• W4286295292 hasAuthorship W4286295292A5042398989 @default.
• W4286295292 hasAuthorship W4286295292A5042746005 @default.
• W4286295292 hasAuthorship W4286295292A5046880629 @default.
• W4286295292 hasAuthorship W4286295292A5059744187 @default.
• W4286295292 hasAuthorship W4286295292A5061542841 @default.
• W4286295292 hasAuthorship W4286295292A5068212661 @default.
• W4286295292 hasAuthorship W4286295292A5075505594 @default.
• W4286295292 hasAuthorship W4286295292A5076979086 @default.
• W4286295292 hasAuthorship W4286295292A5084216361 @default.
• W4286295292 hasAuthorship W4286295292A5089886091 @default.
• W4286295292 hasConcept C121608353 @default.
• W4286295292 hasConcept C126322002 @default.
• W4286295292 hasConcept C143998085 @default.
• W4286295292 hasConcept C144301174 @default.
• W4286295292 hasConcept C167135981 @default.
• W4286295292 hasConcept C207103383 @default.
• W4286295292 hasConcept C2776530083 @default.
• W4286295292 hasConcept C2776833033 @default.
• W4286295292 hasConcept C2779998722 @default.
• W4286295292 hasConcept C2781413609 @default.
• W4286295292 hasConcept C38180746 @default.
• W4286295292 hasConcept C44249647 @default.
• W4286295292 hasConcept C509974204 @default.
• W4286295292 hasConcept C526805850 @default.
• W4286295292 hasConcept C71924100 @default.
• W4286295292 hasConceptScore W4286295292C121608353 @default.
• W4286295292 hasConceptScore W4286295292C126322002 @default.
• W4286295292 hasConceptScore W4286295292C143998085 @default.
• W4286295292 hasConceptScore W4286295292C144301174 @default.
• W4286295292 hasConceptScore W4286295292C167135981 @default.
• W4286295292 hasConceptScore W4286295292C207103383 @default.
• W4286295292 hasConceptScore W4286295292C2776530083 @default.
• W4286295292 hasConceptScore W4286295292C2776833033 @default.
• W4286295292 hasConceptScore W4286295292C2779998722 @default.
• W4286295292 hasConceptScore W4286295292C2781413609 @default.
• W4286295292 hasConceptScore W4286295292C38180746 @default.
• W4286295292 hasConceptScore W4286295292C44249647 @default.
• W4286295292 hasConceptScore W4286295292C509974204 @default.
• W4286295292 hasConceptScore W4286295292C526805850 @default.
• W4286295292 hasConceptScore W4286295292C71924100 @default.
• W4286295292 hasIssue "16_suppl" @default.
• W4286295292 hasLocation W42862952921 @default.
• W4286295292 hasOpenAccess W4286295292 @default.
• W4286295292 hasPrimaryLocation W42862952921 @default.
• W4286295292 hasRelatedWork W1956415942 @default.
• W4286295292 hasRelatedWork W1996158748 @default.
• W4286295292 hasRelatedWork W2006466710 @default.
• W4286295292 hasRelatedWork W2047962734 @default.
• W4286295292 hasRelatedWork W2069688734 @default.
• W4286295292 hasRelatedWork W2110125130 @default.
• W4286295292 hasRelatedWork W2329844376 @default.
• W4286295292 hasRelatedWork W3154194420 @default.
• W4286295292 hasRelatedWork W4280578425 @default.
• W4286295292 hasRelatedWork W4310754871 @default.
• W4286295292 hasVolume "40" @default.
• W4286295292 isParatext "false" @default.
• W4286295292 isRetracted "false" @default.
• W4286295292 workType "article" @default.